Cargando…

Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review

BACKGROUND: Atazanavir/ritonavir is recommended as a preferred second-line antiretroviral regimen in children older than 3 months, alternatively to lopinavir/ritonavir. We performed a systematic review to assess safety and effectiveness of atazanavir use in children and adolescents. METHODS: We sear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saint-Lary, Laura, Dassi Tchoupa Revegue, Marc Harris, Jesson, Julie, Renaud, Françoise, Penazzato, Martina, Townsend, Claire L., O'Rourke, John, Leroy, Valériane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168429/ https://www.ncbi.nlm.nih.gov/pubmed/35676899 http://dx.doi.org/10.3389/fped.2022.913105

Ejemplares similares

Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis
por: Jesson, Julie, et al.
Publicado: (2022)

24-Month Clinical, Immuno-Virological Outcomes, and HIV Status Disclosure in Adolescents Living With Perinatally-Acquired HIV in the IeDEA-COHADO Cohort in Togo and Côte d'Ivoire, 2015–2017
por: Dassi Tchoupa Revegue, Marc Harris, et al.
Publicado: (2021)

Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review
por: O'Rourke, John, et al.
Publicado: (2023)

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review
por: Townsend, Claire L., et al.
Publicado: (2022)

Surviving and Thriving—Shifting the Public Health Response to HIV-Exposed Uninfected Children: Report of the 3rd HIV-Exposed Uninfected Child Workshop
por: Slogrove, Amy L., et al.
Publicado: (2018)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Effect of in utero exposure to HIV and antiretroviral drugs on growth in HIV-exposed uninfected children: a systematic review and meta-analysis protocol
por: Ekali, Gabriel L, et al.
Publicado: (2019)

Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus
por: Colbers, Angela, et al.
Publicado: (2019)

Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis
por: Saint-Lary, Laura, et al.
Publicado: (2023)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe
por: Ngara, Bernard, et al.
Publicado: (2021)

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Pediatric Intensive Care: Immunomodulation With Activated Protein C ex vivo
por: Eliwan, Hassan O., et al.
Publicado: (2019)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir
por: Beckman, Joshua A., et al.
Publicado: (2017)

Mortality and losses to follow‐up among adolescents living with HIV in the IeDEA global cohort collaboration
por: Kariminia, Azar, et al.
Publicado: (2018)

The HIV drug optimization agenda: promoting standards for earlier investigation and approvals of antiretroviral drugs for use in adolescents living with HIV
por: Rojo, Pablo, et al.
Publicado: (2020)

Screening for Anal Dysplasia in Adolescent and Young Adult Men Who Have Sex With Men Living With HIV, a Review of Current Recommendations
por: Addison, Jessica, et al.
Publicado: (2022)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano, Roberto, et al.
Publicado: (2013)

Ureteral Obstruction Due to Radiolucent Atazanavir Ureteral Stones
por: Grant, Michael T., et al.
Publicado: (2017)

Atazanavir Crystal–Induced Chronic Granulomatous Interstitial Nephritis
por: Varghese, Vipin, et al.
Publicado: (2020)

Atazanavir/efavirenz/lamivudine: Covid-19: case report
Publicado: (2021)

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Optimizing drugs to reach treatment targets for children and adolescents living with HIV
por: Penazzato, Martina, et al.
Publicado: (2015)

Locoregional Control and Survival in Children, Adolescents, and Young Adults With Localized Head and Neck Alveolar Rhabdomyosarcoma—The French Experience
por: Machavoine, Roxane, et al.
Publicado: (2022)

Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries
por: Pinto Cardoso, Gaëlle, et al.
Publicado: (2022)

Safety and Tolerability of High Dose Atazanavir–Ritonavir and Lopinavir–Ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study
por: Hocqueloux, Laurent, et al.
Publicado: (2012)

Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
por: Esker, S, et al.
Publicado: (2010)

Long-term treatment of patients with HIV-1: the role of atazanavir
por: Artacho, Miguel Ángel, et al.
Publicado: (2010)

Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis
por: Marinescu, C. I., et al.
Publicado: (2015)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
Publicado: (2013)

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation
por: Leger, Paul, et al.
Publicado: (2018)

Monomorphic ventricular tachycardia due to protease inhibitor intoxication by atazanavir
por: Kim, Byunghyun, et al.
Publicado: (2018)

Cardiovascular outcomes among HIV-infected veterans receiving atazanavir
por: LaFleur, Joanne, et al.
Publicado: (2017)

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
por: Robertson, Kevin, et al.
Publicado: (2018)

Evaluation of a Diagnostic Therapeutic Educational Pathway for Asthma Management in Children and Adolescents
por: Guarnaccia, Sebastiano, et al.
Publicado: (2020)

Effects of strength exercise interventions on activities of daily living, motor performance, and physical activity in children and adolescents with leukemia or non-Hodgkin lymphoma: Results from the randomized controlled ActiveADL Study
por: Gaser, Dominik, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6d4oqti353atklk6pp8hrlrmmj